Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen

Clin Infect Dis. 2011 Feb 15;52(4):547-50. doi: 10.1093/cid/ciq196. Epub 2011 Jan 20.

Abstract

Viral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were similar in the 2 groups (P > .05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alkynes
  • Anti-HIV Agents / administration & dosage*
  • Antiretroviral Therapy, Highly Active / methods
  • Antitubercular Agents / administration & dosage
  • Benzoxazines / administration & dosage*
  • Cyclopropanes
  • Female
  • HIV / isolation & purification*
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • Humans
  • Male
  • Tuberculosis / complications
  • Viral Load*
  • Viremia*

Substances

  • Alkynes
  • Anti-HIV Agents
  • Antitubercular Agents
  • Benzoxazines
  • Cyclopropanes
  • efavirenz